PRESENTATION OUTLINE

- Definitions
- Road Map
- BA/BE Study Reports
- Biowaiver
- Conclusion
DEFINITIONS
DEFINITIONS

- **Bioavailability** – rate and extent at which a drug substance becomes available in the general system.
DEFINITIONS

- **Bioequivalence** – equivalent bioavailability within pre-set acceptance ranges between generic and innovator/comparator.
The main aim in conducting a bioequivalence (BE) study is to demonstrate that the active substance in a generic product is absorbed into the body at the same rate and amount as in the innovator/comparator product. To ensure that the generic product delivers the same therapeutic effect as the innovator/comparator product and is interchangeable.
ROAD MAPS
<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>DCA 92 - review the registration of generic medicines due to increasing complaints on efficacy: Implementation of BE requirement for generic medicines (oral, immediate release, solid dosage form) – in phases</td>
</tr>
<tr>
<td>Sept 1999</td>
<td>The National Working Committee for BE Studies was formed</td>
</tr>
<tr>
<td>Dec 1999</td>
<td>BE 1\textsuperscript{st} List (3 active ingredients – nifedipine, cyclosporine, captopril)</td>
</tr>
<tr>
<td>Feb 2000</td>
<td>BE 2\textsuperscript{nd} List (4 active ingredients – enalapril, lisinopril, piroxicam, acyclovir)</td>
</tr>
<tr>
<td>Sept 2000</td>
<td>Publication of the ‘Malaysian Guidelines for the Conduct of Bioavailability and Bioequivalence Studies’</td>
</tr>
<tr>
<td>Date</td>
<td>Event Description</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>May 2001</td>
<td>BE 3rd List (4 active ingredients – theophylline, propranolol, cimetidine, carbamazepine)</td>
</tr>
<tr>
<td>June 2002</td>
<td>BE 4th List (16 active ingredients)</td>
</tr>
<tr>
<td>April 2003</td>
<td>Implementation of BE for ARVs</td>
</tr>
<tr>
<td>March 04</td>
<td>BE 5th List (16 active ingredients)</td>
</tr>
<tr>
<td>July 2004</td>
<td>‘ASEAN Guidelines for the Conduct of Bioavailability and Bioequivalence Studies’ was adopted</td>
</tr>
<tr>
<td>Aug 2006</td>
<td>BE 6th List (26 active ingredients)</td>
</tr>
<tr>
<td>Date</td>
<td>Event Description</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Aug 2008</td>
<td>BE 7\textsuperscript{th} List (27 active ingredients)</td>
</tr>
<tr>
<td>Sept 2009</td>
<td>BE 8\textsuperscript{th} List (16 active ingredients)</td>
</tr>
<tr>
<td>Jan 2011</td>
<td>BE 9\textsuperscript{th} List (29 active ingredients)</td>
</tr>
<tr>
<td>Jan 2012</td>
<td>BE for all generic medicines (oral, immediate release, solid dosage form)</td>
</tr>
<tr>
<td>Jan 2012</td>
<td>Accreditation of BE Centres (local and overseas)</td>
</tr>
<tr>
<td>Jan 2013</td>
<td>Guidance on Biopharmaceutics Classification System (BCS) - Based Biowaiver</td>
</tr>
<tr>
<td>March 2015</td>
<td>ASEAN Guideline For The Conduct of Bioequivalence Studies (Revision 1, March 2015)</td>
</tr>
<tr>
<td>Date</td>
<td>Implementation Of Bioequivalence Requirements For Generic Products In Dosage Forms Of Oral Effervescent, Dispersible, Orodispersible, Sublingual, Buccal And Chewable Tablets/Capsules - for new application</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>1st July 2016</td>
<td>Implementation Of Bioequivalence Requirements For Generic Products In Dosage Forms Of Oral Effervescent, Dispersible, Orodispersible, Sublingual, Buccal And Chewable Tablets/Capsules – for registered products where the registration expiring from 1st. July 2017</td>
</tr>
</tbody>
</table>
Submission of BE Study Reports- for new application

- Upon submission of application for registration through online
- ACTD,P9 (Product Interchangeability, Equivalence evidence)
- Softcopies (CDs) may be submitted in situation where the size of data has exceeded the size allowed through online
- Report should be compiled according to ASEAN BE Reporting Format
Submission of BE Study Reports- for registered products

- Upon renewal of registration (at least 6 months before the expiry date of registration)
- Hardcopies
- Report should be compiled according to ASEAN BE Reporting Format
- Evaluation through manual system
- Upon completion of evaluation and satisfactory, uploading of complete and approved reports together with approval letter from NPCB onto online system through application for variation
Failure to fulfill BE requirements:

- rejection of new application
- suspension of registration
- cancellation of registration
BIOWAIVER
Biowaiver

- Although the implementation on BE study is compulsory for generic products, in certain circumstances, waivers of BE study (biowaiver) can be considered.
- The term biowaiver is applied to a regulatory approval process when the application (dossier) is approved on the basis of evidence of equivalence other than an *in vivo* bioequivalence test.
BIOWAIVER

LIST A  BIOWAIVERS  LIST C

LIST B
BIOWAIVER (LIST A)

BCS-based biowaiver

Pillars of the BCS

Solubility

Permeability (Absorption)

Dissolution
What does BCS stands for?

Biopharmaceutics Classification System

<table>
<thead>
<tr>
<th>Class I</th>
<th>Class II</th>
</tr>
</thead>
<tbody>
<tr>
<td>High solubility</td>
<td>Low solubility</td>
</tr>
<tr>
<td>High permeability</td>
<td>High permeability</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Class III</th>
<th>Class IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>High solubility</td>
<td>Low solubility</td>
</tr>
<tr>
<td>Low permeability</td>
<td>Low permeability</td>
</tr>
</tbody>
</table>
BIOWAIVER (LIST A)

BCS - Based Biowaiver:
Applicable if:

1. the drug substance has been proven to exhibit high solubility and complete absorption/permeability (BCS Class 1)
2. Either very rapid (>85% within 15min) or rapid (85% within 30min) in vitro dissolution characteristics of the test and reference product has been demonstrated.
BCS-based biowaiver
Evaluation of drug substance

and drug product

Requiring data supporting:

- High solubility of
- High permeability of
- Rapid and similar dissolution of
BIOWAIVER (LIST A)

- Data to support a request for biowaiver:
  1. High solubility profile of the drug substance:
     - the highest single dose is completely soluble in 250 ml or less of aqueous solution at pH 1 - 6.8 (37 °C)
     - requires the investigation in at least three buffers within this range (preferably at pH 1.2, 4.5 and 6.8)
BIOWAIVER (LIST A)

2. Demonstration of complete drug absorption of drug substance in humans high permeability
   - demonstration of complete absorption ie. ≥ 85%
   and normally the complete absorption in human is preferred based on results of pharmacokinetic studies (absolute bioavailability or mass-balance studies)

Peer-reviewed literature may be acceptable from known/established references to describe the drug substance characteristics
3. Demonstration of similar dissolution profiles between generic and reference products ie. comparative dissolution profiles within the range of pH 1-6.8 (at least pH 1.2, 4.5 and 6.8). Determination of dissolution profile similarity between test and reference product: similarity factor ($f_2$). Usage of surfactant in dissolution medium is not allowed.
BIOWAIVER (LIST A)

- Current: Involving 9 drug substances
- The list is not exhaustive and will be reviewed from time to time by the National Committee for BE Study
Guidance on BCS-Based Biowaiver

GUIDANCE ON BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS)-BASED BIOVAIVER

National Pharmaceutical Control Bureau, Ministry Of Health Malaysia.
January 2013

Adopted and adapted mainly from the following:


...to suit local requirements.

TABLE OF CONTENTS

1. INTRODUCTION

2. SUMMARY OF REQUIREMENTS

3. DATA TO SUPPORT A REQUEST FOR BIOVAIVER
3.1 Drug Substance/ Active pharmaceutical ingredient (API)
3.1.1 Solubility
3.1.2 Absorption
3.2 Drug Product
3.2.1 In vitro dissolution
3.2.1.1 General aspects
3.2.1.2 Evaluation of in vitro dissolution results
3.2.2 Excipients
3.3 Fixed Combinations

4. LIST OF DRUG SUBSTANCE/ACTIVE PHARMACEUTICAL INGREDIENTS (API) ALLOWED FOR BIOVAIVER

5. ABBREVIATIONS
BIOWAIVER (LIST B)

- Biowaivers granted based on unavailability of innovator/comparator product for old molecules/drug substance
  ( innovators registered before the implementation of BE requirements in Malaysia ie. before 1999 )
BIOWAIVER (LIST B)

- Issues on the unavailability of comparators have been dealt as case to case basis
- Current: Involving 36 active ingredients
BIOWAIVER (LIST B)

- Data required in lieu of bioequivalence study report:
  1. Process Validation Report (PV) for 3 consecutive batches of product
  2. Comparative Dissolution Profile (CDP) for 3 consecutive batches of product

To prove consistency between batches

- List is not exhaustive and will be reviewed from time to time if and when there are issues on comparator/innovator product
BIOWAIVER (LIST C)

Based on other considerations such as:

1. Product exhibit local effect with no significant systemic absorption

2. Product exhibit different dissolution profile or release specification between innovator (in-house specs.) and generics (pharmacopoeia specs.)

Current: Involving 6 drug substances
BIOWAIVER (LIST C)

- Other requirements may be applied such as special labeling requirements, related *in-vitro* studies (e.g. *in-vitro* binding study), CDP, PV

- List C is not exhaustive and will be reviewed from time to time if and when there are issues
Biowaiver should be considered only when there is an acceptable benefit-risk balance in terms of public health and risk to the individual patient (country specific).

The drug substance allowed for biowaiver should not belong to the group of narrow therapeutic index.

The drug substance allowed for biowaiver should not belong to the group of medicines used to treat critical illness.
Biowaivers will **NOT** be granted automatically to generic products containing the listed drug substances. It will be subjected to the completeness and fulfillment of the requirements and supporting data.
National Pharmaceutical Control Bureau (NPCB) reserves the rights to request for additional information/data not specifically described in guidance to support biowaiver in order to ensure safety, efficacy and quality of generic products.
CONCLUSION
CONCLUSION

All progress and changes made on the bioequivalence requirements for generic products in Malaysia are in tandem with global practice and international standards with some adaptations to suit national requirements, usage and risks.
CONCLUSION

All matters related to BE requirements has been discussed and agreed upon in Technical Working Group and National Committee for BE Study attended by all stakeholders including the industries before they become policies.
WEBSITE FOR FURTHER REFERENCE

www.bpfk.gov.my

- Guidelines
- List of comparators
- BE Study Centres
- Circulars
- Biowaiver
Address: Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
Telephone: +603-78835400
Fax: +603-79562924

THANK YOU